See What HealthDay Can Do For You
Contact Us

Oophorectomy Linked to Better Survival in BRCA1 Breast Cancer

The sooner, the better, researchers found

THURSDAY, April 23, 2015 (HealthDay News) -- Oophorectomy is associated with a decrease in mortality in women with breast cancer and a BRCA1 mutation, and women with estrogen receptor-negative breast cancer and a BRCA1 mutation should undergo the procedure shortly after diagnosis, according to research published online April 23 in JAMA Oncology.

Researchers followed 676 women who had early-stage breast cancers and were carriers of BRCA1 or BRCA2 mutations. The women had received treatment for breast cancer, including mastectomy and lumpectomy. Roughly half had undergone an oophorectomy.

Overall, 77.4 percent of women survived over the 20-year follow-up from time of diagnosis, the findings showed. In women who underwent oophorectomy, the adjusted hazard ratio for breast cancer-specific mortality was 0.38 (95 percent confidence [CI], 0.19 to 0.77; P = 0.007) for BRCA1 carriers and 0.57 (95 percent CI, 0.23 to 1.43; P = 0.23) for BRCA2 carriers. For women with estrogen receptor-positive breast cancer, the hazard ratio for breast cancer-specific mortality was 0.76 (95 percent CI, 0.32 to 1.78; P = 0.53), and for women with estrogen receptor-negative breast cancer, the hazard ratio was 0.07 (95 percent CI, 0.01 to 0.51; P = 0.009).

On average, oophorectomy was done six years after the breast cancer diagnosis, but earlier oophorectomy conferred a greater reduction in breast cancer death risk. The protective effect of oophorectomy was especially strong if women had estrogen receptor-negative breast cancer after age 50.

Full Text

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.